Conium Maculatum 3 X Drops ; Globules ; Granules ; Liquid ; Pellet ; Tablet is a Health Canada–registered human drug (DIN 02233751) held by Seroyal International Inc., containing Conium Maculatum. Health Canada lists its status as Cancelled Post Market (status date 06 Jul 2009). Nexara Health has matched 13 registrations of Conium Maculatum across 2 other regulated markets, 1 of them in the same strength and dosage form.
Health Canada registration
| DIN | 02233751 |
|---|---|
| Brand name | Conium Maculatum |
| Active ingredient | Conium Maculatum |
| Strength | 3 X |
| Dosage form | Drops ; Globules ; Granules ; Liquid ; Pellet ; Tablet |
| Route | Oral |
| Company | Seroyal International Inc. |
| Status | Cancelled Post Market — 06 Jul 2009 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Conium Maculatum registered in other markets
13 registrations of the same molecule in 2 national registries outside Canada (first 9 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | Bestmade Natural Products Conium Maculatum | Bestmade Natural Products | Tablet, Soluble | listed | FDA NDC | |
| United Arab Emirates | Conium Maculatum - Boiron | BOIRON, France, Messimy | 2 DH - 200 CH | Pillules | Active | EDE |
| United States | Conium Maculatum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Conium Maculatum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Conium Maculatum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Conium Maculatum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Conium Maculatum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Conium Maculatum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Conium Maculatum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC |
See every manufacturer of Conium Maculatum worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Conium Maculatum (DIN 02233751) marketed in Canada?
No. Health Canada lists DIN 02233751 as Cancelled Post Market as of 06 Jul 2009.
Who holds the Canadian licence for this product?
Seroyal International Inc. is the company of record in the Health Canada Drug Product Database.
Is Conium Maculatum registered outside Canada?
Yes — Nexara Health has matched 13 registrations in 2 other markets, including 1 in the same strength and dosage form (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02233751, status date 2009-07-06; national medicine registries: EDE, FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02233751, status date 2009-07-06; national medicine registries: EDE, FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02233751, status date 2009-07-06; national medicine registries: EDE, FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.